Cargando…
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
PURPOSE: EGFR tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated lung cancer is limited by acquired resistance. In half of the patients treated with first/second-generation (1st/2nd gen) TKI, resistance is associated with EGFR p.T790M mutation. Sequential treatment with osimertinib is highly ac...
Autores principales: | Kraskowski, Oliver, Stratmann, Jan A., Wiesweg, Marcel, Eberhardt, Wilfried, Metzenmacher, Martin, Schmid, Kurt W., Herold, Thomas, Schildhaus, Hans-Ulrich, Darwiche, Kaid, Aigner, Clemens, Stuschke, Martin, Laue, Katharina, Zaun, Gregor, Kasper, Stefan, Hense, Jörg, Sebastian, Martin, Schuler, Martin, Pogorzelski, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374675/ https://www.ncbi.nlm.nih.gov/pubmed/37198447 http://dx.doi.org/10.1007/s00432-023-04839-3 |
Ejemplares similares
-
Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and (18)F-FDG PET/CT for radiotherapy target volume definition
por: Guberina, Maja, et al.
Publicado: (2021) -
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment
por: Guberina, Nika, et al.
Publicado: (2022) -
Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy
por: Guberina, Maja, et al.
Publicado: (2021) -
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT
por: Guberina, Maja, et al.
Publicado: (2022) -
Lung Cancer Surgery after Neoadjuvant Immunotherapy
por: Stefani, Dirk, et al.
Publicado: (2021)